INTRODUCTION
The Food, Drug and Cosmetic Act of 1958 and amendments require the Food and Drug Administration (FDA) to establish the safety of " all substances ... the intended use of which results or may reasonably be expected to result ... in their becoming a component of food or otherwise affecting the characteristics of food. " 1 The wide range of substances to which this defi nition applies ( Table 1 ) , including unintentional indirect additives, generally precludes clinical testing of most chemicals defi ned as food additives. The extent of safety testing in animals is limited from an economic standpoint as well, since the quantities of many indirect additives produced is small in comparison with those intentionally added to food (direct additives). As a consequence of testing limitations, mathematical extrapolation from results obtained in animals is a key step in the prediction of safety in humans.
Estimation of a level of exposure that is safe invariably translates to fi nding an acceptable mathematical description of the dose-response curve. In cases where exposure to a food additive is low, and/or limited data are available, safety determinations are based on very conservative assumptions and simple models (eg, benchmark dose, linear multistage model) that employ doses to animals in chronic studies in combination with safety factors 3 , 4 to estimate acceptable levels of exposure to human consumers. The safety factors are intended to more than compensate for any differences in response between species, any nonlinearity in the doseresponse curve, and any variance in sensitivity within the human population.
When the use of food additives with specifi c, desirable effects is proposed, exposure levels are generally higher. Establishing the safety of substances at higher levels of exposure requires a more extensive set of safety studies, including studies of the pharmacokinetics and metabolism of the food additive. While this places a greater burden on the manufacturer to conduct experiments and on the FDA to review larger volumes of data, it also creates the need to develop detailed models of the absorption, biological fate, and any physiological effects of the food additive in human consumers. Doseresponse curves can be defi ned with much greater accuracy if pharmacokinetic studies for the new food additive are designed to overlap the dose range(s) used in toxicity studies. 5 However, it is often possible and may be necessary to simulate the disposition of a chemical at higher or lower doses when the chronic study doses used are signifi cantly different from the doses used in pharmacokinetic experiments.
Comparison of the metabolic fate and pharmacokinetics of a food additive between several species of test animals is often the principal means that FDA uses to decide which animal species is most similar to humans, and whether or not an effect observed in a single species of test animals is relevant to humans. Pharmacokinetic analyses may be used primarily for qualitative decisions, such as choosing representative species, or with better data and results from some clinical studies, to make quantitative estimates of acceptable levels of human exposure.
It should be noted that we use mathematical models as learning tools that allow us to (1) convert individual data points from a study into functions that can predict outcomes at points that have not been measured within the range of available data, (2) integrate results from multiple studies into smooth functions, and (3) incorporate untested hypotheses with unknown parameters into models with known parameters to determine the feasibility of different assumptions and the sensitivity of the problem in question to different parameters. Therefore, we do not consider the inability of a model to fi t a set of experimental results to be a failure. Such a result simply means that we did not incorporate enough detail or we did not understand an important component of the pharmacokinetic/pharmacodynamic system. We make changes and try again. Without the model we might never have known that such a knowledge gap existed.
The following examples show ways in which both qualitative and quantitative uses have been made of animal growth models and pharmacokinetic results to better defi ne the systemic dose and evaluate effects of new food additives.
USE OF ANATOMIC/GROWTH MODELS
Accurate extrapolation from the results of animal experiments to outcomes in exposed human populations requires accurate translation of anatomic, physiologic, and biochemical characteristics between test species and humans. Extrapolation of animal toxicity results to humans requires a showing that pharmacokinetic properties and systemic doses of a food additive are similar between test animals and humans. There is generally no one-to-one equivalence between species, and several types of computations must be conducted in order to place boundaries on extrapolations. The fi rst computation we make in reviewing pharmacokinetic data is to determine the mass balance, 5 which is the sum of the masses of tracer in all volumes of distribution and excretion. In some cases, a study is submitted in which tissue concentrations (C i ) of a tracer are reported, but the whole tissue/organ weights are not reported. The mass balance cannot be computed without tissue volumes (V i ) (mass = C i V i ). If the age and/or body weights of the test animals are reported, a good estimate of the organ weight can be made from mathematical models of growth and body and organ weight. [6] [7] [8] Anatomic/growth models are well developed for strains of rats commonly used in toxicological research. Less extensive data and models have been developed for mice and dogs ( Figure 1 ). Models of this type can also be used to estimate the effect of feed restriction when reduced food intake in animals on chronic study complicates the interpretation of toxicity studies. 7 When an adverse effect is observed in a specifi c tissue (target tissue), accurate computations of target tissue concentrations/doses often show dose-effect correlations that would otherwise be less distinct.
Luecke et al 10 , 11 have used human embryonic growth models with doses and effects from animal teratology studies to predict periods of teratogenic sensitivity during human gestation. While the use of such models is limited by the availability of data sets useful for animal-to-human extrapolation, they provide anatomically accurate tissue volumes and physiological parameter values from which pharmacokinetic and pharmacodynamic results can be used to extrapolate effects across species.
PREDICTION OF SYSTEMIC DOSES FROM LIMITED KINETIC DATA

Time-to-Effect Versus Dose
It is well known that certain toxic effects can only be produced by long-term exposure to a chemical, either because the probability of the initiating event is low, or because a defi ciency of some sort (eg, mineral or vitamin defi ciency) must be produced before the physiological change underlying the effect can occur. Some examples of this type of situation are shown in Figure 2A . Laboratory rats and mice have been bred to achieve a variety of pathological characteristics, including spontaneous occurrence of cancer. Murray 12 described the incidence and time of appearance of mammary Figure 2B might go unobserved for some chemicals. Rozman 15 has shown that differences between chemicals in Dose x t = Effect behavior is often the result of differences in pharmacokinetic characteristics of the chemicals. Thus, the inability of experimenters to achieve a physiological change and observe the development of an effect within the short lifetime of a test species can be exacerbated by a failure to achieve an equivalent systemic dose between test species. It is therefore important to be able to determine the target tissue dose for test species in subchronic and chronic studies and to ensure that systemic exposures are computed, since the dose provided in the food or other delivery vehicle may not be equally absorbed or may be eliminated more rapidly in different test animal species.
The FDA usually receives results of subchronic and chronic toxicity studies without analyses of tissues that would tell us the target tissue dose. However, we often receive pharmacokinetic study data that include tissue concentrations Figure 1 . Fitted body and organ growth curves from Roth et al 5 and data of Deavers et al. 9 Male beagle body weights were fi tted to the Gompertz equation:
The parameter a is sensitive to food consumption and diet quality. The parameter b is constant for a species/strain. Fitted parameter values for male beagles were a = 0.0595/day, b = 0.0163/day.
Figure 2. (A) Mammary tumors do not appear in untreated C3H
mice until 40% of the mice die from other causes (data from Murray 12 ). Note that the mortality rate accelerates once tumors begin to form. (B) Expected Survival (N(t)) for ad libitum fed and feed-restricted (F-R) rats (data from Ross 13 ) overlaid on tumor incidence plot for rats treated with 0.15 mg/kg-day DENU. 14 Actual survival would be reduced as tumors form. Survival curves were generated by fi tting survival data from Ross 13 to the function N( t ) = N 0 exp{( − q x /r x )[e rx t − 1]}, where N 0 is the total number of animals at time 0; q x is the mortality rate at age 0; and r x is the acceleration of mortality with time.
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that may allow us to use pharmacokinetic models to estimate target tissue concentration during the conduct of subchronic and chronic studies.
Example: Gender Differences in Tissue Partitioning and Effects
In a recent submission reviewed by FDA, the target tissue of an antioxidant (HP-136) appeared to be the liver. The chemical in question produced hepatic infl ammation and necrosis at doses above 50 mg/kg-day in female rats but produced no effects in male rats below 1000 mg/kg-day. No measurements of tissue concentrations of HP-136 were available from the chronic study.
A limited pharmacokinetic study had been conducted, with oral dosing, which showed low levels of gastrointestinal (GI) absorption (<15% of dose) and rapid disappearance of label from the plasma. Only 1 set of tissue samples was taken, at 96 hours postdose. However, these values were pivotal, showing that concentrations in the fat and liver were 30 to 100 times higher than the rapidly disappearing levels in plasma. We used the Liver:Plasma and Fat:Plasma ratios at 96 hours as partition coeffi cients, incorporated these parameters into a blood-fl ow limited pharmacokinetic model, and simulated the dosing conditions of the chronic study (results shown in Figure 3 ). Female rats were predicted to accumulate very high levels of HP-136 in the liver during the chronic study, while fat was the most accumulative tissue in males -a strong correlation between toxicity and target tissue dose. This outcome suggested that binding to a female-specifi c cytochrome P450 or other hepatic binding protein was involved.
Without more mechanism-specifi c information we were not able to determine whether these phenomena were relevant to humans, but the pharmacokinetic models of the rat gave the FDA a stronger argument for reducing exposure levels than we would have had with chronic study results alone. Even if human studies were conducted, information on tissue levels would never have been available from clinical studies. When tissue residue data are available in animals, tissue-blood partition coeffi cients can be estimated and used with anatomical models to perform extrapolations like that shown in Table 2 . Such extrapolations are chiefl y useful for checking mass balances in clinical studies but, once validated, can be very useful in evaluating experiment designs by simulation of outcomes.
Since target-tissue concentration data are rarely ever provided with submissions of chronic study results, simple models (see Figure 4 ) are often used to simulate plasma concentrations, and where more detailed ADME data are available, concentrations in specifi c tissues may be simulated. In fact, it has been our experience that the results from a good pharmacokinetic study enable us to accurately predict the outcome of multiple dosing studies and chronic dosing studies.
In some cases, a product sponsor may provide the FDA with suffi cient pharmacokinetic data and/or a model containing suffi cient detail to be called a physiologically based model. A model of this type is what is usually required in order to simulate concentrations of chemicals in specifi c tissues. While instances of the use of such models by product sponsors are rare, we do encourage the use of such models since the data provided are generally of higher quality and are directed toward answering mechanistic questions rather than giving us qualitative answers that may be much more diffi cult to extrapolate to humans.
Example: Solubility Limitation on Bioavailability/Dose
An example from another recent submission involved the limitation of chronic study doses by low water solubility of the food additive being tested. Doses implied by levels incorporated into the food of animals on chronic study ranged from a few mg/kg-day to more than 1 g/kg-day.
Although pharmacokinetic studies provided by the sponsor did not extend to the highest doses used in the chronic studies, some analyses of plasma levels were available from chronic studies and indicated that absorption was lower at high doses. When the aqueous solubility for this additive 
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was incorporated into the pharmacokinetic model via a dissolution submodel, the model predictions were very similar to plasma concentrations observed in the chronic study ( Figure 5 ). In this case it could be concluded that the systemic dose achieved by providing ~500 mg/kg-day in the diet would have been essentially equal to that provided by the higher doses. Had any adverse effects been observed, they would likely have been very similar from 500 mg/kgday up to the top dose, whatever that number might have been. In this case, the models were useful primarily as a means of clarifying experimental results rather than as a means of predicting the outcome of human exposures.
SELECTION OF REPRESENTATIVE SPECIES BY COMPARISON OF METABOLITES, PHARMACOKINETICS
The FDA may receive pharmacokinetic data for more than 1 species for high-volume/high-exposure food additives.
These data are generally accompanied by toxicity studies for the same animal species. When clinical pharmacokinetic studies are available as well, it becomes possible to compare the metabolism and pharmacokinetics between humans and multiple test species. If possible, we would like to select toxicity studies from the species most similar to humans as the basis for predicting the human doseresponse (where any unwanted effects occur) and estimating acceptable exposures. We try to use the simplest pharmacokinetic models possible, but in our experience the simplest models that are able to fi t major features of GI absorption and plasma elimination curves contain 5 to 7 compartments. These models include a stomach (No. 1), a small intestine (No. 2), one or more blood (plasma) compartments (No. [3] [4] , and at least 1 tissue compartment (No. 5-6) (see Figure 5 ). Using such models it has been possible to fi t and perform quantitative comparison between test animals and humans with respect to absorption rates, elimination rates, blood:tissue partitioning, and differences in 16 ‡ Tissue/plasma concentration ratios computed from rat study data.
metabolites produced ( Figures 6 and 7 ) . More important than the curve fi tting required for estimation of the absorption and elimination parameters is the prediction of systemic exposures in humans and test species by test conditions and proposed food-additive use levels. Small differences between species in absorption and metabolism may combine to yield similar or very different systemic concentra- Figure 5 . Effect of solubility on delivered dose versus systemic dose (maximum plasma concentration achieved). In this case, the test substance was delivered by gavage in a fi xed volume. The 150-and 500-mg/kg doses were given in suspension. Figure 6 . Example of the use of model shown in Figure 5 to fi t oral dosing data. Parameter values for intestinal absorption (k a(i) ) and gastric emptying of fl uids (E 01 ) from a gavage dosing experiment were combined with estimates for systemic elimination (k e ) and emptying of solids (E 01 ) to simulate plasma levels of parent chemical (neotame) and its metabolite after dosing in food. tions. Exposures are usually computed as areas under the curve (AUC = C i (t) dt).
In the case of neotame, relatively small differences in basic ADME parameters combine to give a very large difference 
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in systemic exposure ( Figure 8 ). The normal safety factor approach (~100-fold between humans and most sensitive test species) would not have provided a suffi cient margin of safety if any toxicity had been associated with this food additive. Total systemic exposure (AUC = ò C(t) dt) to neotame in humans is 600-fold higher than in the rat.
CONCLUSION
The estimation of a " safe " level of human exposure to new food additives has never been an exact procedure and relies on safety studies of varying quality and quantity. The accumulation of historical data on growth and physiology in humans and animals has allowed the development of mathematical models that can provide a reliable and robust means of extrapolating from the available data sets to obtain better dose-response curves and other information we would like to have when performing safety assessments. Without such models, we would often be reduced to hand-waving arguments and piling on additional safety factors in order to achieve " safe " levels of food-additive exposure. 
